Get the Stockscreener App
4.27
1.39%
-0.06
After Hours:
4.22
-0.05
-1.17%
Prelude Therapeutics Inc stock is traded at $4.27, with a volume of 241.37K.
It is down -1.39% in the last 24 hours and down -0.93% over the past month.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
See More
Previous Close:
$4.33
Open:
$4.37
24h Volume:
241.37K
Relative Volume:
0.61
Market Cap:
$340.09M
Revenue:
$16.72M
Net Income/Loss:
$-77.80M
P/E Ratio:
-4.0386
EPS:
-1.0573
Net Cash Flow:
$-43.78M
1W Performance:
-4.69%
1M Performance:
-0.93%
6M Performance:
+155.69%
1Y Performance:
+374.39%
1-Day Range:
$4.16
$4.52
1-Week Range:
$3.95
$4.75
52-Week Range:
$0.75
$5.54
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.27 | 344.86M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
New PROTACs reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Sahm
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech - Investing.com India
Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives - Sahm
TradingKey - TradingKey
Jefferies raises Prelude Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia
Prelude (PRLD) Reports Progress on Strategic Initiatives and Cas - GuruFocus
Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028 - Minichart
Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension - ChartMill
Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary - TradingView
Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update - Quiver Quantitative
Prelude Therapeutics Q1 net loss narrows as expenses fall - TradingView
Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028 - Stock Titan
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Weekly Voice
Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD - Moomoo
Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet - Yahoo Finance
Prelude Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00 - GuruFocus
D. Boral Capital Initiates Prelude Therapeutics(PRLD.US) With Buy Rating, Announces Target Price $9 - Moomoo
D Boral Capital initiates coverage of Prelude Therapeutics (PRLD) with buy recommendation - MSN
Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat
Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat
HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat
RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada
PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat
Thursday’s insider trading: Major buys at Prelude, sells at NuScale - Investing.com
Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock - MarketBeat
Insider Purchase: Director at $PRLD Buys 1,689,189 Shares - Moomoo
Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com - Investing.com Canada
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock - Investing.com
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock By Investing.com - Investing.com South Africa
Orbimed entities acquire $12.5m in Prelude Therapeutics stock - Investing.com
OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering - Stock Titan
OrbiMed funds boost Prelude Therapeutics (NASDAQ: PRLD) stake with 2.82M-share buy - Stock Titan
Prelude Therapeutics Enters Underwriting for $85.5 Million Equity Offering Led by RA Capital - TradingView
Prelude Therapeutics (PRLD) Unveils Promising Preclinical Data f - GuruFocus
Prelude Therapeutics (PRLD) Launches $90M Public Offering with S - GuruFocus
Prelude Therapeutics Shares Rise on Positive Preclinical Data for Breast Cancer Drug - Moomoo
Prelude Therapeutics Unveils Promising Preclinical Data for First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer at AACR 2026 12 - Minichart
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Apr 21 '26 |
Buy |
4.44 |
2,815,315 |
12,499,999 |
11,808,945 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):